Superworth

Tarsus Pharmaceuticals price to book ratio TARS

Market value divided by the book value of the company's net assets, since 2021.

Today, Nov 2, 2026
9.3×
6-year median
3.8×
Against its 6-year history
95th
percentile: 0 is its lowest day, 100 its highest
6-year range
1.4× to 11.5×
Peer median
5.8×

Tarsus Pharmaceuticals' price to book ratio is 9.3× as of Nov 2, 2026.

That is above its 6-year median of 3.8×, higher than on 95% of days in the last 6 years.

Over that time it ranged from 1.4× in May 2022 to 11.5× in Sep 2026.

The median for 10 biotech stocks of a similar size is 5.8×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far9.3×7.2×11.5×
202510.4×4.8×10.4×
20248.9×3.0×8.9×
20233.1×1.6×3.9×
20221.9×1.4×2.6×
20212.6×2.3×4.1×

Against its peers

Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
TARSTarsus Pharmaceuticals9.3×
ADMAAdma Biologics6.1×
VCELVericel5.6×
KRYSKrystal Biotech6.4×
RGENRepligen4.6×
TECHBIO-TECHNE5.4×
MGTXMeiraGTx4.2×
HALOHalozyme Therapeutics102×
NBIXNeurocrine Biosciences4.0×
EXELExelixis9.4×
ALNYAlnylam Pharmaceuticals15.7×
Peer median5.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Tarsus Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.